Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer’s drug success
admin Next stop regulatory approval. That was the view of analysts at Mizuho Securities, who late…
Read MoreCommercial Banking
Eisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
Eisai Co. shares were indicated sharply higher Wednesday morning after the Japanese drug maker and…
Read MoreAlzheimer’s drug from Eisai, Biogen shows promise in large trial
Eisai Co. 4523, +0.89% and Biogen Inc. BIIB, +1.04% said their experimental Alzheimer’s disease drug…
Read MoreBig banks to pay nearly $2 billion for ‘widespread and longstanding failures’ in keeping text-message records
Nearly a dozen financial institutions agreed to pay more than $1.8 billion collectively for failing…
Read MoreBank of America clients are buying the dip in U.S. stocks, shifting from cyclicals to defensive
In light of the recent U.S. stock market losses, Bank of America (BofA) saw more…
Read MoreGlobal bonds are in first bear market in 76 years based on two centuries of data, says Deutsche Bank
It’s been a terrible year for financial markets and perhaps even more so when you…
Read MoreCitrix debt deal prices with large losses for banks
Investment banks including Bank of America Corp., Credit Suisse Group AG and Goldman Sachs Group…
Read MoreSenators drill down on Zelle reimbursements, inflation and ‘uber-woke’ policies in bank CEO hearing
Democratic senators criticized banks for not serving consumers fairly while Republicans complained about liberal social…
Read MoreCredit Suisse shares drop after report of fresh capital raise
Credit Suisse Group AG shares fell sharply in early Friday trading after a media report…
Read More
Opinion: New York’s $250 million lawsuit against Donald Trump is the beginning, not end, of this case—a tax lawyer explains what’s at stake
New York Attorney General Letitia James hit former president Donald Trump with a $250 million…
Read More